Curesponse
About
Curesponse is a personalized medicine company that provides a functional drug sensitivity testing platform to guide cancer treatment. Their technology aims to predict patient response to various therapies by testing drugs on live tumor samples, thereby improving treatment accuracy and patient outcomes.
Key facts
At-a-glance profile data
- Website
- curesponse.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2017
- Employees
- 14
- Total funding
- $28M (Series B)
- Business model
- B2B
Funding rounds
Tech stack
Detected on curesponse.com, last scanned 3 Aug 2026. Run your own scan
- Hosting
- Google Cloud
Add first review
Frequently asked
How much funding has Curesponse raised?
Curesponse has raised a total of $28M in funding. The most recent round on record is Series B.
How many employees does Curesponse have?
Curesponse has approximately 14 people on record.
What is Curesponse's current status?
Curesponse's current operating status is: Inactive.